{"schema_version":"secwatch.filing_event.v1","accession":"0001372514-24-000099","form_type":"8-K","ticker":"KPRX","cik":"0001372514","company_name":"KIORA PHARMACEUTICALS INC","filed_at":"2024-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.817766+00:00","generated_at":"2026-05-31T15:08:57.610286+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kiora Pharma receives EU orphan designation for KIO-301 in inherited retinal dystrophies","bullets":["EMA grants Orphan Medicinal Product Designation for KIO-301 in non-syndromic rod-dominant retinal dystrophies including retinitis pigmentosa.","Provides at least 10 years of market exclusivity in Europe, reduced fees, centralized approval, and EMA scientific advice.","KIO-301 already has US Orphan Drug Designation; Phase 2 ABACUS-2 trial expected to initiate later in 2024.","KIO-301 is a small molecule photoswitch designed to restore light sensing in degenerated retinas, a non-gene therapy approach.","Co-development and commercialization partner Théa Open Innovation covers ex-Asia territories."],"urls":{"canonical":"https://secwatch.observer/filing/0001372514-24-000099","json":"https://secwatch.observer/filing/0001372514-24-000099.json","markdown":"https://secwatch.observer/filing/0001372514-24-000099.md","text":"https://secwatch.observer/filing/0001372514-24-000099.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000099/0001372514-24-000099-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372514/000137251424000099/kprx-20240730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T15:08:57.610286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}